公开(公告)号：AU2015378564A1

公开(公告)日：2017-07-13

申请号：AU2015378564

申请日：2015-08-21

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  WONG CHI-HUEY

IPC: G01N33/53

Abstract: The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.

公开(公告)号：AU2015267047A1

公开(公告)日：2017-01-05

申请号：AU2015267047

申请日：2015-05-27

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  TSAI MING-HUNG ,  WONG CHI-HUEY

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：CA2959030A1

公开(公告)日：2016-02-25

申请号：CA2959030

申请日：2015-08-21

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  LEE HSIN-YU

IPC: C07K14/33 ,  C07K14/34

Abstract: This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.

公开(公告)号：HK1207668A1

公开(公告)日：2016-02-05

申请号：HK15108043

申请日：2015-08-19

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSAI TSUNG-I

IPC: C12P20060101 ,  C12N20060101

Abstract: A novel UDP-Gal regeneration process and its combined use with a galactosyltransferase to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

公开(公告)号：CA2950440A1

公开(公告)日：2015-12-03

申请号：CA2950440

申请日：2015-05-27

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：CA2882294A1

公开(公告)日：2014-02-27

申请号：CA2882294

申请日：2013-08-20

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSAI TSUNG-I

IPC: C12P19/04 ,  C12N9/10

Abstract: A novel UDP-Gal regeneration process and its combined use with a galactosyltransferease to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

公开(公告)号：DK2318832T3

公开(公告)日：2014-01-20

申请号：DK09798721

申请日：2009-07-15

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  TSENG SUSAN Y ,  WONG CHI-HUEY

IPC: C40B40/12 ,  C40B50/14

公开(公告)号：MX2010013932A

公开(公告)日：2013-03-01

申请号：MX2010013932

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU JOHN ,  YU ALICE

IPC: A61K39/00 ,  A61K39/385

Abstract: Se proporcionan composiciones inmunogénicas, vacunas de cáncer y métodos para tratar cáncer. Se proporcionan composiciones que comprenden: (a) un glicano tal como Globo H o un fragmento inmunogénico del mismo, en donde el glicano está conjugado con una proteína portadora mediante un enlazador tal como para-nitrofenilo; y (b) un adyuvante que comprende glucolípido capaz de enlazar CDId sobre una célula dendrítica, tal como un derivado de a-galactosilceramida, en donde la composición inmunogénica induce una respuesta inmune que induce un nivel relativo más alto de anticuerpos de isotipo IgG como es comparado con los anticuerpos de isotipo IgM. Se proporcionan composiciones inmunogénicas que comprenden el material de reacción cruzada de toxina de difteria de proteína portadora 197 (DT-CRM 197) y el adyuvante C34. Los anticuerpos generados por las composiciones inmunogénicas divulgadas en la presente además neutralizan por lo menos uno de los antígenos Globo H, antígeno embriónico específico de etapa-3 (SSEA-3) y antígeno embriónico específico de etapa-4 (SSEA-4). Terapias contra células madre de cáncer de seno que comprenden composiciones inmunogénicas que comprenden Globo H, SSEA-3 o SSEA-4 conjugado con DT-CRM 197.

公开(公告)号：NZ590140A

公开(公告)日：2012-07-27

申请号：NZ59014009

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

IPC: A61K39/00 ,  A61K39/385

Abstract: Disclosed is an immunogenic composition comprising: (a) a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker; and (b) an adjuvant including C34, wherein C34 is defined in the specification. Also disclosed is the use of the immunogenic composition in the manufacture of a medicament for the treatment or inhibition of tumor growth, wherein administration of medicament induces au immune response that produces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies.

公开(公告)号：CA2728341A1

公开(公告)日：2010-01-14

申请号：CA2728341

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

IPC: A61K39/00 ,  A61K39/385

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CDId on a dendritic cell, such as an a-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM 197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM 197.